Raymond James & Associates Has $2.96 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Raymond James & Associates grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) by 79.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 74,854 shares of the biopharmaceutical company’s stock after buying an additional 33,149 shares during the quarter. Raymond James & Associates’ holdings in Halozyme Therapeutics were worth $2,960,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Horizon Advisors Inc. increased its stake in shares of Halozyme Therapeutics by 188.8% in the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 472 shares in the last quarter. Meeder Asset Management Inc. increased its position in Halozyme Therapeutics by 223.6% in the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 512 shares during the period. Brown Brothers Harriman & Co. acquired a new stake in Halozyme Therapeutics in the second quarter worth about $35,000. Selective Wealth Management Inc. acquired a new stake in Halozyme Therapeutics in the second quarter worth about $44,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in Halozyme Therapeutics in the second quarter worth about $57,000. 96.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on HALO shares. Benchmark lifted their price objective on Halozyme Therapeutics from $55.00 to $68.00 and gave the stock a “buy” rating in a research report on Thursday, December 8th. JMP Securities lifted their price objective on Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 9th. JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $53.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 22nd. Wells Fargo & Company started coverage on Halozyme Therapeutics in a research report on Monday, November 28th. They issued an “overweight” rating and a $65.00 price objective for the company. Finally, SVB Leerink reduced their target price on Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating on the stock in a report on Wednesday, January 11th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $59.63.

Halozyme Therapeutics Trading Up 0.3 %

NASDAQ:HALO opened at $51.46 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $31.36 and a fifty-two week high of $59.46. The company has a debt-to-equity ratio of 15.37, a current ratio of 5.97 and a quick ratio of 5.03. The stock has a market capitalization of $6.96 billion, a PE ratio of 34.54, a price-to-earnings-growth ratio of 0.65 and a beta of 1.23. The business’s 50-day simple moving average is $55.31 and its 200-day simple moving average is $48.30.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last released its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.21. Halozyme Therapeutics had a return on equity of 134.71% and a net margin of 36.37%. The business had revenue of $208.98 million for the quarter, compared to analysts’ expectations of $187.87 million. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 2.07 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $54.13, for a total transaction of $541,300.00. Following the transaction, the senior vice president now owns 163,137 shares in the company, valued at approximately $8,830,605.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $54.13, for a total value of $541,300.00. Following the sale, the senior vice president now owns 163,137 shares in the company, valued at approximately $8,830,605.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $53.81, for a total value of $269,050.00. Following the completion of the sale, the chief financial officer now owns 4,045 shares in the company, valued at approximately $217,661.45. The disclosure for this sale can be found here. Insiders have sold 85,000 shares of company stock worth $4,666,350 in the last 90 days. Corporate insiders own 2.30% of the company’s stock.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.